{'fraction_non_alphanumeric': 0.044340723453908985, 'fraction_numerical': 0.028004667444574097, 'mean_word_length': 4.376175548589342, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Overtreatment of prostate cancer may be prevented by extended pelvic lymphadenectomy.

OBJECTIVE
Pelvic lymphadenectomy remains the gold standard for providing a diagnosis of lymph node metastasis (N1) in prostate cancer patients who may be candidates for curatively intended radiotherapy (RT). The limited lymphadenectomy technique (L-PLND) provides removal of only a minority of lymph nodes within the expected regions of lymph node drainage of the prostate. We describe our extended lymphadenectomy (e-PLND) and the pathological outcome with a modified template as described by Briganti and compare it with L-PLND.


MATERIAL AND METHODS
This was a retrospective study of 44 patients who underwent e-PLND and 36 patients who underwent L-PLND. The lymph node dissection regions were divided into: I the external iliac field, II the obturator field and III the internal iliac field.


RESULTS
The mean age was 70.2 years for e-PLND and 68.9 years for L-PLND. There was no significant difference in preoperative prostate-specific antigen (PSA), Gleason score or clinical stage between the two cohorts of patients. The mean operative time was 95 min. (range 75-140 min.) for e-PLND and 82 min. (range 30-145 min.) for L-PLND (p = 0.03). N1 was found in 18 (41%) and six (17%) in e-PLND versus L-PLND, respectively (p = 0.03). Six of the 44 (13.6%) patients who underwent e-PLND had N1 exclusively outside the region related to the limited dissection technique.


CONCLUSION
e-PLND is safe and can prevent overtreatment of at least 13.6% of the prostate cancer patients who may be candidates for RT. Positive needle-core biopsies have a direct impact on N1.


FUNDING
not relevant.


TRIAL REGISTRATION
not relevant.